Hans Schambye

Galec­to reaps $64M to bring lead drug across IPF fin­ish line, while mak­ing moves in NASH and be­yond

Back in 2018, Hans Scham­bye raised $90 mil­lion to kick off a late-stage tri­al that could put Galec­to Biotech’s lead drug on the fi­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.